UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2011
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-34753
Genmark Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 27-2053069 | |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
| 5964 La Place Court, Suite 100, Carlsbad, California | 92008-8829 | |
| (Address of principal executive offices) | (Zip code) | |
Registrants telephone number, including area code: 760-448-4300
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
| Non-accelerated filer | x | Smaller reporting company | ¨ | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
The number of outstanding shares of the registrants common stock on April 30, 2010 was 12,337,489.
| Page | ||||||
| PART I - FINANCIAL INFORMATION | ||||||
| Item 1. | Financial Statements | 1 | ||||
| Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations | 9 | ||||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 15 | ||||
| Item 4. | Controls and Procedures | 15 | ||||
| PART II -OTHER INFORMATION | ||||||
| Item 1. | Legal Proceedings | 16 | ||||
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 16 | ||||
| Item 3. | Defaults Upon Senior Securities | 16 | ||||
| Item 4. | (Removed and Reserved) | 17 | ||||
| Item 5. | Other Information | 17 | ||||
| Item 6. | Exhibits | 17 | ||||
| ITEM 1. | FINANCIAL STATEMENTS |
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
As
of
March 31, 2011 |
As
of
December 31, 2010 |
|||||||
|
Current assets |
||||||||
|
Cash and cash equivalents |
$ | 17,054,095 | $ | 18,329,079 | ||||
|
Accounts receivable, net |
762,272 | 677,648 | ||||||
|
Inventories, net |
871,033 | 896,809 | ||||||
|
Other current assets |
382,194 | 2,193,160 | ||||||
|
Total current assets |
19,069,594 | 22,096,696 | ||||||
|
Property and equipment, net |
2,762,362 | 2,702,478 | ||||||
|
Intangible assets, net |
68,042 | 70,980 | ||||||
|
Other long-term assets |
55,355 | 55,355 | ||||||
|
Total assets |
$ | 21,955,353 | $ | 24,925,509 | ||||
|
Current liabilities |
||||||||
|
Accounts payable |
$ | 1,651,985 | $ | 823,242 | ||||
|
Accrued compensation |
1,019,545 | 1,171,989 | ||||||
|
Other current liabilities |
1,761,011 | 1,249,928 | ||||||
|
Total current liabilities |
4,432,541 | 3,245,159 | ||||||
|
Long-term liabilities |
||||||||
|
Loan payable |
2,000,000 | | ||||||
|
Other non-current liabilities |
622,644 | 612,932 | ||||||
|
Total liabilities |
$ | 7,055,185 | $ | 3,858,091 | ||||
|
Stockholders equity |
||||||||
|
Common stock, $.0001 par value; 100,000,000 authorized; 11,738,233 and 11,723,512 issued and outstanding as of March 31, 2011 and December 31, 2010, respectively |
1,172 | 1,172 | ||||||
|
Preferred stock, $0.0001 par value; 5,000,000 authorized, none issued |
| | ||||||
|
Additional paid-in capital |
166,483,672 | 166,009,084 | ||||||
|
Accumulated deficit |
(151,134,719 | ) | (144,492,881 | ) | ||||
|
Accumulated other comprehensive loss |
(449,957 | ) | (449,957 | ) | ||||
|
Total stockholders equity |
14,900,168 | 21,067,418 | ||||||
|
Total liabilities and stockholders equity |
$ | 21,955,353 | $ | 24,925,509 | ||||
See accompanying notes to unaudited condensed consolidated financial statements.
1
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
Three Months
Ended
March 31, |
||||||||
| 2011 | 2010 | |||||||
|
Product Revenue |
$ | 692,739 | $ | 384,249 | ||||
|
License and other revenue |
71,664 | 15,015 | ||||||
|
Total revenue |
764,403 | 399,264 | ||||||
|
Cost of sales |
1,643,456 | 567,396 | ||||||
|
Gross loss |
(879,053 | ) | (168,132 | ) | ||||
|
Operating expenses |
||||||||
|
Sales and marketing |
1,130,389 | 1,058,285 | ||||||
|
General and administrative |
2,111,336 | 2,167,264 | ||||||
|
Research and development |
2,528,252 | 1,453,759 | ||||||
|
Total operating expenses |
5,769,977 | 4,679,308 | ||||||
|
Loss from operations |
(6,649,030 | ) | (4,847,440 | ) | ||||
|
Other income |
||||||||
|
Other income (expense) |
11,899 | (1,110 | ) | |||||
|
Interest income |
6,258 | 4,654 | ||||||
|
Total other income |
18,157 | 3,544 | ||||||
|
Loss before income taxes |
(6,630,873 | ) | (4,843,896 | ) | ||||
|
Provision for income taxes |
(10,968 | ) | (5,049 | ) | ||||
|
Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
|
Net loss per share, basic and diluted |
$ | (0.56 | ) | $ | (0.68 | ) | ||
|
Weighted average number of shares outstanding |
11,771,014 | 7,113,922 | ||||||
|
Condensed consolidated statements of comprehensive loss three and three months ended March 31, 2011 and 2010 |
||||||||
|
Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
|
Foreign currency translation adjustment |
| (34,647 | ) | |||||
|
Comprehensive loss |
$ | (6,641,841 | ) | $ | (4,883,592 | ) | ||
See accompanying notes to unaudited condensed consolidated financial statements.
2
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
Three Months
Ended
March 31, |
||||||||
| 2011 | 2010 | |||||||
|
Cash flows from operating activities: |
||||||||
|
Net loss |
$ | (6,641,841 | ) | $ | (4,848,945 | ) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Depreciation and amortization |
288,771 | 318,369 | ||||||
|
Change in allowance for doubtful accounts, net of write-offs |
(47,785 | ) | | |||||
|
Change in allowance for excess and obsolete inventory |
(546 | ) | | |||||
|
Share-based compensation |
474,588 | 347,530 | ||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Trade accounts receivable |
(36,839 | ) | (71,316 | ) | ||||
|
Inventories |
26,322 | (65,138 | ) | |||||
|
Other current assets |
1,810,966 | (469,561 | ) | |||||
|
Accounts payable |
667,559 | (316,564 | ) | |||||
|
Accrued compensation |
(152,444 | ) | 279,184 | |||||
|
Accrued and other liabilities |
520,798 | (155,724 | ) | |||||
|
Net cash used in operating activities |
(3,090,451 | ) | (4,982,165 | ) | ||||
|
Investing activities: |
||||||||
|
Purchases of property and equipment |
(184,533 | ) | (137,440 | ) | ||||
|
Net cash used in investing activities |
(184,533 | ) | (137,440 | ) | ||||
|
Financing activities: |
||||||||
|
Proceeds of loan payable |
2,000,000 | | ||||||
|
Proceeds from stock option exercises |
| 4,734 | ||||||
|
Net cash provided by financing activities |
2,000,000 | 4,734 | ||||||
|
Effect of foreign exchange rate changes |
| (46,935 | ) | |||||
|
Net decrease in cash and cash equivalents |
(1,274,984 | ) | (5,114,871 | ) | ||||
|
Cash and cash equivalents at beginning of period |
18,329,079 | 16,482,818 | ||||||
|
Cash and cash equivalents at end of period |
$ | 17,054,095 | $ | 11,321,012 | ||||
|
Noncash investing and financing activities: |
||||||||
|
Reclassification of deposits on systems in other current assets |
| $ | 285,284 | |||||
|
IPO costs incurred but not paid included in accounts payable |
| 1,537,192 | ||||||
|
Property and equipment costs incurred but not paid included in accounts payable |
$ | 161,184 | | |||||
See accompanying notes to unaudited condensed consolidated financial statements.
3
Genmark Diagnostics, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
| 1. | Organization and basis of presentation |
Genmark Diagnostics, Inc. (the Company or GenMark) is a molecular diagnostics company focused on developing and commercializing the Companys proprietary e-sensor technology. On February 12, 2010, the Company was established to serve as the parent company of Osmetech plc (Osmetech) upon a corporate reorganization and initial public offering (IPO). On June 3, 2010, the Company completed an IPO for 4,600,000 shares. Immediately prior to the completion of the IPO, the Company underwent a corporate reorganization whereby the ordinary shares of Osmetech were exchanged by its shareholders for the common stock of the Company on a 230 for 1 basis.
As the reorganization is deemed to be a transaction under common control, GenMark accounted for the reorganization in a manner similar to a pooling-of-interests, meaning:
(i) assets and liabilities were carried over at their respective carrying values;
(ii) common stock was carried over at the nominal value of the shares issued by GenMark;
(iii) additional paid-in capital represents the difference between the nominal value of the shares issued by GenMark, and the total of the additional paid-in capital and nominal value of Osmetechs shares cancelled pursuant to the described reorganization; and
(iv) the accumulated deficit represents the aggregate of the accumulated deficit of Osmetech and the Company.
Once the reorganization became effective, all stock options granted under the Osmetech plc 2003 U.S. Equity Compensation Plan, Long Term Incentive Awards and all warrants issued were exchanged for options and warrants exercisable for the common stock of the Company.
The preferred stock may be issued from time to time in one or more series.
In these consolidated financial statements, the Company means Osmetech when referring to periods prior to the corporate reorganization and IPO.
The Company evaluated subsequent events through May 13, 2011, being the date of issuance of the unaudited condensed consolidated financial statements.
The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of $151,134,719 at March 31, 2011. Cash and cash equivalents at March 31, 2011 were $17,054,095.
Management expects operating losses to continue through the foreseeable future until the Company has expanded its product offerings and increased its product revenues to an extent covers the fixed cost base of the business. The Companys management has prepared cash flow forecasts which indicate, based on the current cash resources available and the availability of unutilized credit facilities, that the Company has sufficient capital to fund its operations for at least the next twelve months.
The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for audited financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2011 are not necessarily indicative of the results that may be expected for the year ending December 31, 2011. The information presented in the condensed consolidated financial statements and related footnotes at March 31, 2011, and for the three months ended March 31, 2011 and 2010, is unaudited and the condensed consolidated balance sheet amounts and related footnotes at December 31, 2010 have been derived from our audited financial statements. For further information, refer to the consolidated financial statements and accompanying footnotes included in our annual report Form 10-K filed with the Securities and Exchange Commission (SEC) on March 14, 2011.
4
Genmark Diagnostics, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
The Company operates in one reportable segment, and substantially all of the Companys operations and assets are in the United States of America.
Principles of Consolidation -The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.
Fair Value of Financial Instruments
The Companys financial instruments consist of cash equivalents, accounts receivable, accounts payable and loan payable. The carrying amounts of accounts receivable, accounts payable and the loan payable are considered reasonable estimates of their fair value, due to the short maturity of these instruments. There were no significant financial instruments requiring one-time or recurring measurements of fair value during the three months ended March 31, 2011.
Accounting literature provides a fair value hierarchy, which classifies fair value measurements based on the inputs used in measuring fair value. These inputs include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. There were no transfers of items between Levels 1, 2 or 3.
Cash and cash equivalents: The carrying amounts reported in the balance sheets for cash and cash equivalents are stated at their fair market value. Cash and cash equivalents are classified as Level 1.
Loan payable : The carrying amount reported in the balance sheets for the loan payable is considered a reasonable estimate of fair value, based on the short maturity and comparable terms for similar credit facilities. The loan payable is classified as Level 2.
Non-recurring measurements: The Company measures the fair value of its long-lived assets on a periodic basis when it appears that there may be requirement to do so, such as an indication of impairment. There was no impairment recorded for the three months ended March 31, 2011.
Income Taxes
Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Companys deferred tax assets due to the uncertainty surrounding the Companys ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest and penalties related to uncertain tax positions as a component of income tax expense.
5
Genmark Diagnostics, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
| 2. | Share-Based Compensation |
The Company recognizes share-based compensation expense related to share options, warrants and restricted stock issued to employees, directors and consultants in exchange for services. The compensation expense is based on the fair value of the awards, which are determined by utilizing various assumptions regarding the underlying attributes of the options and shares. The estimated fair value of options granted and restricted stock, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense on a straight line basis over the period the vesting occurs. The share-based compensation expense is recorded in cost of sales, sales and marketing, research and development and general and administrative expenses based on the employees or consultants respective function. The option and warrant-related expense is derived from the Black-Scholes Option Pricing Model that uses several judgment based variables to calculate the expense. The inputs include the expected life of the option or warrant, the expected volatility and other factors. The compensation expense related to the restricted stock is calculated as the difference between the fair market value of the stock on the date of grant, less the cost to acquire the shares, which is $0.0001 per share.
On June 3, 2010, the Company exchanged all of the outstanding options under the Osmetech plc 2003 U.S. Equity Compensation Plan (the U.S. Plan) for options under the 2010 Equity Incentive Plan (the Plan). The options were exchanged using an exchange ratio of 230 options to purchase shares of Osmetech plc to one share of the Company and was accounted for as a modification of the share-based payment arrangement. There was no additional compensation cost recorded related to the exchange as there was no change in the economic value of the options exchanged.
Employee participation in the Plan is at the discretion of the compensation committee or senior management of the Company. All options granted since June 3, 2010 are exercisable at a price equal to the average closing quoted market price of the Companys shares on the NASDAQ on the date of grant. Options granted prior to June 3, 2010 under the Osmetech plc 2003 U.S. Equity Compensation Plan were exercisable at a price equal to the average closing quoted market price of the Osmetech plcs shares on the Alternative Investment Market of the London Stock Exchange on the date of the grant as adjusted for the exchange ratio to the Companys shares as described above. Options generally vest between 1 and 4 years.
Options are generally exercisable for a period up to 10 years after grant and are forfeited if the employee leaves the Company before the options vest. As of March 31, 2011, 701,957 shares remained available for future grant of awards under the Plan. Restricted stock grants reduce the amount of stock options available for grant under the 2010 Plan and are excluded from the table below.
The following table summarizes stock option activity during the three months ended March 31, 2011:
|
Number of
Share options |
Weighted average
exercise price |
|||||||
|
Outstanding at December 31, 2010 |
1,107,920 | $ | 6.40 | |||||
|
Granted |
226,500 | 4.37 | ||||||
|
Exercised |
| | ||||||
|
Cancelled |
(19,445 | ) | (0.37 | ) | ||||
|
Outstanding at March 31, 2011 |
1,314,975 | $ | 6.06 | |||||
|
Exercisable at March 31, 2011 |
516,596 | $ | 7.12 | |||||
As of March 31, 2011, there were 1,314,975 options that are vested or expected to vest and these options have a remaining weighted average contractual term of 8.63 years, and an aggregate intrinsic value of $0.
During the three months ended March 31, 2011, the Company granted 130,800 shares of restricted stock to senior management employees and 10,000 shares of restricted stock to an outside consultant. The restricted stock granted to senior management employees vests over a four year period except for 4,000 shares of restricted stock issued to one employee as part of a separation agreement that vests May 31, 2011. The restricted stock granted to the outside consultant vested on March 1, 2011 commensurate with the period of service rendered to the Company.
6
Genmark Diagnostics, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
Valuation of Share-Based Awards The Black-Scholes option pricing model was used for estimating the grant date fair value of stock options granted during the three months ended March 31, 2011 with the following assumptions:
|
Expected volatility (%) |
70.0 | |||
|
Expected life (years) |
6.08 | |||
|
Risk free rate (%) |
2.51 | |||
|
Expected dividend yield (%) |
0 |
| 3. | Net Loss Per Common Share |
Basic net loss per share is computed by dividing loss available to common shareholders (the numerator) by the weighted average number of common shares outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued unless the effect would be anti-dilutive. As the Company had a net loss in each of the periods presented, basic and diluted net loss per ordinary share are the same.
The computations of diluted net loss per share did not include the effects of the following securities as the inclusion of these items would have been anti-dilutive:
| Three months ended March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Share options |
1,314,975 | 960,624 | ||||||
|
Warrants |
88,317 | 88,317 | ||||||
|
Restricted Stockvested; not issued or outstanding |
61,057 | | ||||||
| 1,464,349 | 1,048,941 | |||||||
Common Stock Warrants During 2009, the Company issued warrants to purchase 132,475 of Osmetechs ordinary shares with an exercise price of £4.60 per share, and warrants to purchase 88,317 of Osmetechs ordinary shares with an exercise price of £6.90 per share to a director for services to the Company in connection with the share offering completed in 2009. Pursuant to the terms of the warrant, the warrant to purchase 132,475 was cancelled upon the closing of the IPO in June 2010. At the same time, the warrant to purchase 88,317 of Osmetechs ordinary shares was converted to warrants to purchase 88,317 shares of the Companys common stock at an exercise price of $9.98. These warrants were fully vested and exercisable upon issue, and shall continue to be exercisable up to and including the earlier to occur of (i) 60 days after the director leaving the Companys board of directors (for whatever reason) and (ii) June 30, 2012.
| 4. | Property and Equipment, net |
Property and equipment was comprised of the following as of March 31, 2011 and December 31, 2010:
|
March 31,
2011 |
December 31,
2010 |
|||||||
|
Property and equipmentat cost: |
||||||||
|
Plant and machinery |
$ | 2,473,579 | $ | 2,451,775 | ||||
|
Rental systems |
3,125,399 | 2,821,665 | ||||||
|
Office equipment |
1,548,235 | 1,541,544 | ||||||
|
Leasehold improvements |
611,021 | 597,523 | ||||||
|
Total property and equipmentat cost |
7,758,234 | 7,412,506 | ||||||
| Less accumulated depreciation | (4,995,872 | ) | (4,710,029 | ) | ||||
| Net property and equipment | $ | 2,762,362 | $ | 2,702,478 | ||||
Depreciation expense amounted to $285,833 and $198,687 for the three months ended March 31, 2011 and 2010, respectively.
7
Genmark Diagnostics, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
| 5. | Loan payable |
In March 2010, the Company entered into a loan and security agreement with Square 1 Bank, pursuant to obtaining a credit facility consisting of a revolving line of credit in the amount of up to $2 million and an equipment term loan in the amount of up to $2 million. Based upon certain financial covenants, interest on the revolving line of credit will be either (i) the greater of (a) the banks prime rate (3.25% as of March 31, 2011) plus 2.75%, or (b) 6%; or (ii) the greater of (a) the banks prime rate plus 3.75%, or (b) 7%. In addition, based upon certain financial covenants, interest on the equipment term loan will be either (i) the greater of (a) the banks prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the banks prime rate plus 4.25%, or (b) 7.50%. The revolving line matures in July 2011 and the term loan matures in July 2013. In March 2011, the loan and security agreement was amended, whereby the line of credit availability was increased to $3 million and the maturity was extended to July 2012. The term loan was modified to allow invoices up to 360 days to qualify to be submitted for credit extension. There were no other changes to these two loans.
In March 2011, an additional loan was made available under the amended loan and security agreement for up to $1.0 million to finance equipment purchases. Based upon certain financial covenants, interest on this equipment term loan will be either (i) the greater of (a) the banks prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the banks prime rate plus 4.25%, or (b) 7.50%. This term loan matures March 2014.
As of March 31, 2011, the Company had no outstanding loans on the line of credit or the 2011 equipment loan and had drawn $2.0 million to finance 2010 equipment purchases and tenant improvements to its Carlsbad facility against the original 2010 equipment term loan. The loan bears an interest rate of 6.5%.
Pursuant to the terms of the loan and security agreement, we are required to maintain a ratio of liquidity to bank indebtedness equal to at least 1.50 to 1.00. In addition, the loan and security agreement includes several restrictive covenants, including requirements that we obtain the consent of Square 1 Bank prior to entering into any change of control event unless all debt is repaid to Square 1 Bank prior to the change of control event, incurring other indebtedness or liens with respect to our property, making distributions to our stockholders, making certain investments or entering into certain transactions with affiliates and other restrictions on storing inventory and equipment with third parties. The agreement also limits the amount we can borrow under the term loan to license genetic biomarkers to $500,000. To secure the credit facility, we granted Square 1 Bank a first priority security interest in our assets and intellectual property rights. We are currently in compliance will all ratios and covenants.
| 6. | Income taxes |
The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.
As of March 31, 2011, the Company has recorded a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the Companys ability to utilize these assets in the future. Provision for income tax was $11,000 and $5,000 for the three months ended March 31, 2011 and 2010, respectively. Due to the Companys losses it only records tax provision or benefit related to minimum tax payments or refunds and interest and penalties related to its uncertain tax positions.
The total amount of unrecognized tax benefits was $382,000 as of March 31, 2011 which would impact the effective tax rate if recognized. The gross liability for income taxes related to unrecognized tax benefits is included in other long-term liabilities in the Companys condensed consolidated balance sheets.
The total balance of accrued interest related to uncertain tax positions was $104,770 as of March 31, 2011. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
The Company is subject to taxation in the U.S., UK based on its legacy operations, and in various state jurisdictions. As of March 31, 2011 the Companys tax years after 2007 are subject to examination by the UK tax authorities. Except for net operating losses generated in prior years carrying forward to the current year, as of March 31, 2011, the Company is no longer subject to U.S. federal, state, local or foreign examinations by tax authorities for years before 2006.
8
| ITEM 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations |
The following discussion of our financial condition and results of operations should be read with our unaudited condensed consolidated financial statements and notes included in Item 1 of this Quarterly Report for the three months ended March 31, 2011, as well as the audited financial statements and notes and Managements Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2010, included in our annual report Form 10-K dated March 11, 2011 filed with the SEC. This Managements Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management including, without limitation, our expectations regarding our results of operations, sales and marketing expenses, general and administrative expenses, research and development expenses, and the sufficiency of our cash for future operations. Words such as we expect, anticipate, target, project, believe, goals, estimate, potential, predict, may, will, expect, might, could, intend, variations of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements.
Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading Risk Factors in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2010 and any risk factors described under the heading Risk Factors in Item 1A of Part II of this Quarterly Report. We do not intend to update these forward looking statements to reflect future events or circumstances.
Overview
GenMark Diagnostics, Inc., or GenMark, was formed by Osmetech plc, or Osmetech, in Delaware in February 2010 and had no operations prior to its initial public offering which was completed in June 2010. Immediately prior to the closing of the initial public offering, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of (i) the issuance of common stock of GenMark to the former shareholders of Osmetech and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a subsidiary controlled by GenMark, and the former shareholders of Osmetech began to hold shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization.
We are a molecular diagnostics company focused on developing and commercializing our proprietary eSensor detection technology. Our proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. Our XT-8 system received 510(k) clearance from the Food and Drug Administration, or FDA, and is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified DNA sample, our XT-8 system produces clear and accurate results. Our XT-8 system supports up to 24 independent test cartridges, which can be run independently, resulting in a highly convenient and flexible workflow for our target customers, which are hospitals and reference laboratories.
We have developed four diagnostic tests for use with our XT-8 system and expect to expand this test menu by introducing two to four new tests annually. Our Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, our Warfarin Sensitivity Test, which determines an individuals ability to metabolize the oral anticoagulant warfarin, and our Thrombophilia Risk Test, which detects an individuals increased risk of blood clots, have received FDA clearance. Our eSensor technology has demonstrated 100% accuracy in clinical studies compared to DNA sequencing in our Cystic Fibrosis Genotyping Test, our Warfarin Sensitivity Test and our Thrombophilia Risk Test. We have also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses and is labeled for investigational use only, or IUO. We intend to seek FDA clearance for our Respiratory Viral Panel Test in 2011. We also have a pipeline of several additional potential products in different stages of development or design, including diagnostic tests for an individuals sensitivity to Plavix, a commonly prescribed anti-coagulant, and for mutations in a gene known as K-ras, which is predictive of an individuals response rates to certain prescribed anti-cancer therapies.
9
We are also developing our next-generation platform, the NexGen system. We are designing the NexGen system to integrate DNA amplification with our eSensor detection technology to enable technicians using the NexGen system to be able to place a raw or minimally prepared patient sample into our test cartridge and obtain results without any additional steps. This sample to answer capability is enabled by the robust nature of our eSensor detection technology, which is not impaired by sample impurities that we believe hinder competing technologies. We are designing our NexGen system to further simplify workflow and provide powerful, cost-effective molecular diagnostics solutions to a significantly expanded group of hospitals and reference laboratories.
Since inception, we have incurred net losses from continuing operations each year, and we expect to continue to incur losses for the foreseeable future. Our losses attributable to continuing operations for the three months ended March 31, 2011 and 2010 were approximately $6.6 million and $4.8 million, respectively. As of March 31, 2011, we had an accumulated deficit of $151.1 million. Our operations to date have been funded principally through sales of capital stock and sales of our previous businesses. We expect to incur increasing expenses over the next several years, principally to develop additional diagnostic tests, as well as to further increase our spending to manufacture, sell and market our products.
Results of Operations Three months ended March 31, 2011 compared to the three months ended March 31, 2010
Revenue
| March 31, | ||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||
|
Three months ended |
$ | 764,403 | $ | 399,264 | $ | 365,139 | 91 | % | ||||||||
The increase in revenue for the three
month period ended March 31, 2011 as compared to the three month period ended March 31, 2010 was primarily due to a $331,000 increase in reagent revenue driven by the increase in number of our installed base of systems as well as an
Cost of Sales and Gross Loss
| March 31, | ||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||
|
Cost of Sales-three months ended |
$ | 1,643,456 | $ | 567,396 | $ | 1,076,060 | 190 | % | ||||||||
|
Gross Loss -three months ended |
$ | 879,053 | $ | 168,132 | $ | 710,921 | 423 | % | ||||||||
The increase in cost of sales for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 was due to $605,000 in increased expenses related directly to the increase in reagent and system shipments, as well as costs incurred in relocating our manufacturing facilities from Pasadena to our Carlsbad location in 2011, including $314,000 in higher payroll, benefits and temporary labor costs and $188,000 of additional facility-related charges. The increase in gross loss resulted primarily from costs associated with our expanded product offerings which will be reduced as a percentage of sales as our sales volume increases, and the one-time expense of relocating our manufacturing facility which should be completed by the end of the second quarter of 2011.
10
Operating Expenses
Sales and Marketing
| March 31, | ||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||
|
Three months ended |
$ | 1,130,389 | $ | 1,058,285 | $ | 72,104 | 7 | % | ||||||||
The increase in sales and marketing expense was driven primarily by increased costs for product samples sent to prospective customers.
General and Administrative
| March 31, | ||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||
|
Three months ended |
$ | 2,111,336 | $ | 2,167,264 | $ | (55,928 | ) | (3 | )% | |||||||
General and administrative expense decreased for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 due to $925,000 in lower payroll, severance and other headcount related costs associated with our former UK operations and lower facility-related costs. These reductions were offset by a $370,000 increase in professional services fees primarily related to corporate restructuring, and $550,000 in additional consulting, share-based compensation and recruiting costs for executive services.
Research and Development
| March 31, | ||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||
|
Three months ended |
$ | 2,528,252 | $ | 1,453,759 | $ | 1,074,493 | 74 | % | ||||||||
The increase in research and development expense for the three months ended March 31, 2011 was due to $150,000 in higher payroll expense due to increased headcount, severance related expenses of $239,000, increased development supplies and clinical trial costs of $160,000, a $133,000 increase in intellectual property related costs, costs of $250,000 incurred to obtain regulatory certification for our Carlsbad manufacturing facility and $117,000 of increased facility related costs in 2011 as compared to the same period in 2010.
11
Other Income, Net
| March 31, | ||||||||||||||||||||
| 2011 | 2010 | $ Change | % Change | |||||||||||||||||
|
Three months ended |
$ | 18,157 | $ | 3,544 | $ | 14,613 | 412 | % | ||||||||||||
Interest and other income (expense) represent earnings on cash and cash equivalents and foreign currency gains or losses. The increase in revenue for the three months ended March 31, 2011 as compared to the same period in 2010 was due primarily to a foreign currency gain related to accounts receivable from the UK in 2010 that was received in 2011 at higher foreign currency translation rates. During the second quarter of 2010, the Company shut down its UK facility and changed its functional currency to the U.S. dollar. There are no remaining material operations in the UK.
Provision for Income Taxes
| March 31, | ||||||||||||||||
| 2010 | 2009 | $ Change | % Change | |||||||||||||
|
Three months ended |
$ | 10,968 | $ | 5,049 | $ | 5,919 | 117 | % | ||||||||
Due to the Companys losses it has only recorded tax provisions or benefits related to interest on uncertain tax positions, minimum tax payments and refunds.
Liquidity and Capital Resources
To date we have funded our operations primarily from the sale of our common stock and revenues. We have incurred net losses from continuing operations each year and have not yet achieved profitability. At March 31, 2011, we had $14.7 million of working capital, including $17.1 million in cash and cash equivalents.
Cash Flows
The following table summarizes, for the periods indicated, selected items in our consolidated statements of cash flows:
| March 31, | ||||||||
| 2011 | 2010 | |||||||
|
Three months ended: |
||||||||
|
Cash used by operating activities |
$ | (3,090,451 | ) | $ | (4,982,165 | ) | ||
|
Cash used by investing activities |
(184,533 | ) | (137,440 | ) | ||||
|
Cash provided by financing activities |
2,000,000 | 4,734 | ||||||
|
Decrease in cash and cash equivalents |
$ | (1,274,984 | ) | $ | (5,114,871 | ) | ||
Cash flows used by operating activities
Net cash used in operating activities decreased $1.9 million to $3.1 million for the three months ended March 31, 2011 compared to $5.0 million for the three months ended March 31, 2010. The decreased use of cash was due primarily to collection of a $1.6 million therapeutic tax credit and $1.2 million of higher accounts payable and accrued liabilities in the current quarter, partially offset by accrued IPO costs at March 31, 2010 that were subsequently paid in 2010.
12
Cash flows used by investing activities
Net cash used in investing activities increased $48,000 to $185,000 for the three months ended March 31, 2011 compared to $137,000 for the three months ended March 31, 2010 primarily due to increased purchases of our XT-8 systems used for customer rentals which are included in property and equipment.
Cash flows provided by financing activities
Net cash provided by financing activities increased by $2.0 million for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 resulting from proceeds of a loan payable drawn in March 2011 to finance equipment purchases and tenant improvements purchased in 2010.
In March 2010, we entered into a loan and security agreement with Square 1 Bank, pursuant to which we obtained a credit facility consisting of a revolving line of credit in the amount of up to $2 million and an equipment term loan in the amount of up to $2 million. Based upon certain financial covenants, interest on the revolving line of credit will be either (i) the greater of (a) the banks prime rate (3.25% as of March 31, 2011) plus 2.75%, or (b) 6%; or (ii) the greater of (a) the banks prime rate plus 3.75%, or (b) 7%. In addition, based upon certain financial covenants, interest on the equipment term loan will be either (i) the greater of (a) the banks prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the banks prime rate plus 4.25%, or (b) 7.50%. The revolving line matures in July 2011 and the term loan matures in July 2013. In March 2011, the loan and security agreement was amended, whereby the line of credit availability was increased to $3 million and the maturity was extended to July 2012. The term loan was modified to allow invoices up to 360 days to qualify to be submitted for credit extension. There were no other changes to these two loans.
In March 2011, an additional loan was made available under the amended loan and security agreement for up to $1 million to finance equipment purchases. Based upon certain financial covenants, interest on this equipment term loan will be either (i) the greater of (a) the banks prime rate plus 3.25%, or (b) 6.50%; or (ii) the greater of (a) the banks prime rate plus 4.25%, or (b) 7.50%. This term loan matures March 2014.
As of March 31, 2011, the Company had no outstanding loans on the line of credit or the 2011 equipment loan and had drawn $2.0 million to finance 2010 equipment purchases and tenant improvements to its Carlsbad facility against the original 2010 equipment term loan. The loan bears an interest rate of 6.5%.
Pursuant to the terms of the loan and security agreement, we are required to maintain a ratio of liquidity to bank indebtedness equal to at least 1.50 to 1.00. In addition, the loan and security agreement includes several restrictive covenants, including requirements that we obtain the consent of Square 1 Bank prior to entering into any change of control event unless all debt is repaid to Square 1 Bank prior to the change of control event, incurring other indebtedness or liens with respect to our property, making distributions to our stockholders, making certain investments or entering into certain transactions with affiliates and other restrictions on storing inventory and equipment with third parties. The agreement also limits the amount we can borrow under the term loan to license genetic biomarkers to $500,000. To secure the credit facility, we granted Square 1 Bank a first priority security interest in our assets and intellectual property rights. We are currently in compliance will all ratios and covenants.
The Companys management has prepared cash flow forecasts which indicate, based on the current cash resources available, the availability of unutilized credit facilities, and our ability to access the equity markets will be sufficient to fund our business for at least the next 12 months. We expect capital outlays and operating expenditures to increase over the next several years as we grow our customer base and revenues, expand our research and development, commercialization and manufacturing activities. The amount of additional capital we may need to raise in the future depends on many factors, including:
| |
the level of revenues and the rate of revenue growth; |
| |
the level of expenses required to expand our sales and marketing activities; |
13
| |
the level of research and development investment required to maintain and improve our technology; |
| |
our need to acquire or license complementary technologies or acquire complementary businesses; |
| |
the costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; |
| |
competing technological and market developments; and |
| |
changes in regulatory policies or laws that affect our operations. |
We cannot be certain that additional capital will be available when and as needed or that our actual cash requirements will not be greater than anticipated. If we require additional capital at a time when investment in diagnostics companies or in the marketplace in general is limited due to the then prevailing market or other conditions, we may not be able to raise such funds at the time that we desire, on acceptable terms, or at all. In addition, if we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. If we obtain additional debt financing, a substantial portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, and the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates including those related to bad debts, inventories, valuation of intangibles and other long-term assets, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and there have been no material changes during the three months ended March 31, 2011.
Contractual Obligations
On February 8, 2010, we entered into a seven-year and seven-month lease for a new 31,098 square foot facility in Carlsbad, California. The facility is part of a three-building office and research and development project located at 5964 La Place Court, Carlsbad, California, and the project totals 158,733 rentable square feet. Monthly rental payments of $45,092 commenced on July 14, 2010 and increase 3% annually thereafter. We also pay our pro-rata share of the building and project maintenance, property tax, management and other costs subject to certain limitations. We have paid a $55,000 security deposit and provided a $500,000 standby letter of credit as security for the future rent as well as for up to $2.0 million in landlord funded tenant improvements. The lease also provides for rights of first refusal for expansion within our building, subject to certain limitations.
On February 28, 2011, we entered into a 36 month operating lease for office equipment with total lease payments of $85,000. In conjunction with the lease, the lessor paid the Company approximately $27,000 to payoff previous contracts for similar equipment leased from a different vendor.
14
Other Off-Balance Sheet Arrangements
We have no other off-balance sheet arrangements except for our unutilized credit facilities with Square 1 Bank that provides a revolving line of credit up to $2 million and an unutilized equipment term loan totalling $1 million at March 31, 2011.
| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of less than three months. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, in the future we may maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. We currently do not hedge interest rate exposure. Because of the short-term maturities of our cash equivalents, we do not believe that an increase in market rates would have a material negative impact on the value of our portfolio.
Interest Rate Risk
Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio. The fair market value of fixed rate securities may be adversely impacted by fluctuations in interest rates while income earned on floating rate securities may decline as a result of decreases in interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 10% adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments.
Foreign Currency Exchange Risks
All of our operating facilities are located within the United States. We are a U.S. entity and our functional currency is the U.S. dollar. Virtually all of our revenues are based in the United States. A small portion of our expenses in the first quarter of 2010, relating to our corporate office, were transacted in British pounds. We currently have no material operations outside of the United States which diminishes the extent of any foreign currency exchange risk.
| ITEM 4. | CONTROLS AND PROCEDURES |
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (Exchange Act), is recorded, processed, summarized and reported within the timelines specified in the SECs rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we carried out an evaluation of the effectiveness of the Companys disclosure controls and procedures (as such term is defined in Exchange Act Rules 13a 15(e) and 15d 15(e)) as of March 31, 2011. Based on such evaluation, our management has concluded that as of March 31, 2011, the Companys disclosure controls and procedures are effective.
15
Changes in Internal Control over Financial Reporting
As required by Rule 13a-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer and principal financial officer concluded no such changes during the period covered by this Quarterly Report on Form 10-Q materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.
| ITEM 1. | LEGAL PROCEEDINGS |
We are from time to time subject to various claims and legal actions during the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.
| ITEM 1A. | RISK FACTORS |
An investment in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described under Item 1A of Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2010 (the Risk Factors), together with all other information contained or incorporated by reference in this report before you decide to invest in our common stock. If any of the risks described in this report or in our Annual Report on Form 10-K actually occurs, our business, financial condition, results of operations and our future growth prospects could be materially and adversely affected. Under these circumstances, the trading price of our common stock could decline, and you may lose all or part of your investment. There have been no material changes to the Risk Factors since the filing of our Annual Report.
| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Unregistered Sales of Equity Securities
None
Use of Proceeds from Registered Securities
On June 3, 2010, we closed our initial public offering, in which we sold 4,600,000 shares of common stock at a price to the public of $6.00 per share. The aggregate offering price for shares sold in the offering was $27.6 million. The offer and sale of all of the shares in the initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-165562), which was declared effective by the SEC on May 28, 2010. The offering commenced as of May 28, 2010 and did not terminate before all of the securities registered in the registration statement were sold. Piper Jaffray acted as sole book-running manager for the offering. William Blair & Company and ThinkEquity LLC acted as co-managers of the offering. There were no selling stockholders in the offering. We raised approximately $22.6 million in net proceeds after deducting underwriting discounts and commissions of $1.9 million and other offering expenses of $3.0 million. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on June 1, 2010 pursuant to Rule 424(b). We invested the funds received in registered money market funds.
| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
None.
16
| ITEM 4. | (REMOVED AND RESERVED). |
| ITEM 5. | OTHER INFORMATION. |
None.
| ITEM 6. | EXHIBITS. |
The exhibits listed in the Exhibit Index are incorporated herein by reference.
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| GENMARK DIAGNOSTICS, INC. | ||||||
| Date: May 13, 2011 |
/s/ Paul Ross |
|||||
| Paul Ross | ||||||
| Chief Financial Officer | ||||||
| (principal financial and accounting officer) | ||||||
18
EXHIBIT INDEX
Listed and indexed below are all Exhibits filed as part of this report.
| 10.30# | Separation Agreement and General Release dated March 24, 2011, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Pankaj Singhal (incorporated by reference to Exhibit 10.1 on our Form 8-K filed with the Commission on March 28, 2010). | |
| 10.31# | Employee Offer Letter, dated March 11, 2011, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Paul Ross (incorporated by reference to Exhibit 10.1 on our Form 8-K/A filed with the Commission on April 7, 2011). | |
| 10.32# | Executive Employment Agreement dated March 1, 2010, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Jeffrey Hawkins. | |
| 10.33# | Executive Consulting Agreement dated October 12, 2010, by and between Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc. and Kuranda Partners, LLC. | |
| 10.34# | Executive Employment Agreement, dated April 5, 2011, by and between GenMark Diagnostics, Inc. and Hany Massarany. | |
| 31.1 | Certification of Principal Executive Officer Required Under Rule13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended | |
| 31.2 | Certification of Principal Financial Officer Required Under Rule13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. | |
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350. | |
| # | Indicates management contract or compensatory plan. |
Exhibit 10.32
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (Agreement) is entered into as of March 1, 2010 (Effective Date), by Osmetech Technology, Inc. and subsidiaries (Company) and Jeffrey Hawkins (Executive). Company and Executive are each a Party to this Agreement and are sometimes collectively referred to as Parties. This Agreement supersedes any previous written or verbal agreements.
Recitals Of The Intent Of The Parties
A. The Company wishes to employ Executive, and Executive wishes to accept such employment.
B. Executive acknowledges that this Agreement is necessary for the protection of Companys investment in its business, goodwill, products, services, methods of operation, information, and relationships with its customers and other employees; and
C. Company acknowledges that Executive desires definition of the compensation and benefits, and other terms of employment;
Agreement Of The Parties
In consideration of foregoing recitals, the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the Company and Executive agree as follows:
1. Employment . Company employs Executive, and Executive agrees to be employed by Company, upon the terms and conditions set forth in this Agreement beginning on the Effective Date and continuing until terminated by either Party pursuant to the terms of this Agreement.
2. Duties .
2.1. Basic Duties . Executive agrees to serve as Vice President of Business Development, reporting to the Chief Executive Officer and with such other powers, duties and responsibilities usually vested in his position as well as additional or different duties that Executive may be reasonably directed to perform by Company.
2.2. Time Devoted to Employment . Executive will devote his full time to the business of Company during the term of this Agreement and will perform his duties and responsibilities faithfully, diligently and to the best of his ability, in compliance with all applicable laws and the Companys policies and procedures. Executive will not engage in any other business activity, except as may be approved in writing by the Chief Executive Officer of Company, in its sole discretion.
2.3. Place of Performance . Executive shall be based at Companys offices in Pasadena, California until such time as the Company relocates to the San Diego Area. The Executive will be required to travel on Companys business from time-to-time.
2.4. No Conflicting Agreements . Executive represents and warrants that the performance of Executives duties under this Agreement does not and will not breach any other agreement, including any confidentiality and non-disclosure agreements with prior employers or other
CONFIDENTIAL
persons. Executive represents and warrants that Executive has not entered into, and will not enter into, any agreement, either written or oral in conflict with this Agreement. Executive represents that Executive has disclosed to Company any actual or potential conflicts.
2.5. Duty of Loyalty . Executive acknowledges and agrees that Executive owes a fiduciary duty of loyalty, fidelity and allegiance to act at all times in the best interests of the Company and to do no act which would intentionally injure Companys business, its interests, or its reputation. Executive understands that it is Companys policy to conduct its business ethically and legally and agrees to uphold those standards of business conduct and ethical principles, and comply with all applicable laws and regulations and Companys policies.
3. Compensation and Method of Payment .
3.1. Total Compensation . As compensation under this Agreement, Company will pay and Executive will accept the following:
3.1.1. Executive will receive on an annual basis of One Hundred Ninety Thousand Dollars ($190,000.00) (Base Salary). The Company will review Executives Base Salary annually and may, in its sole discretion increase the Executives Base Salary, considering Executives achievements during the prior period, business conditions and other factors as may be deemed relevant by Company.
3.1.2. Executive will be eligible to participate in the Management Incentive Bonus of up to 25% variable pay based on current base salary, which will be defined on an annual basis and requires approval by the Board of Directors. Executive will only earn and be entitled to a Management Incentive Bonus if Executive is employed on the date the bonus is payable and Company will not pay prorated Management Incentive Bonus in the event of Executives earlier departure.
3.1.3. The Company will also offer Executive participation in the OMD stock incentive program. Executive has been granted 9,800,660 options to purchase shares of Osmetech Stock per the current plan policies and procedures which included Board of Directors approval.
3.1.4. The Company will assist Executive with relocation costs in the amount of $70,000.00 (less all applicable local, state and federal taxes) to be applied to such things as house hunting trips, moving of household items, home sale closing costs, etc. This assistants will be paid in two installments. One half ($35,000), to be paid at Executives request. The second portion ($35,000) will be paid upon completion of relocation in the form of a signed escrow agreement on a new home within San Diego County, no later than September 30 th , 2010.
3.1.5. Company will reimburse Executive for all reasonable travel, entertainment and other expenses incurred or paid by Executive in connection with the performance of Executives duties, responsibilities or services under this Agreement, upon presentation by the Executive of documentation as Company may request and in accordance with any applicable policies adopted by the Company.
3.1.6. Executive will be entitled to participate in employee fringe benefit, health insurance, life insurance, and other programs which Company may adopt from time to time for executives of Company. Participation will be in accordance with any plans and any applicable policies adopted by Company. Executive will be entitled to accrue 15 days (120 hours) of vacation in accordance with Company policy in effect from time to time and subject to applicable state law.
2
CONFIDENTIAL
3.2. Reservation of Rights . Notwithstanding any other provision of this Agreement, Company reserves the right to modify, suspend or discontinue any and all benefit plans, practices, policies and programs at any time whether before or after termination of employment without advance notice to or recourse by Executive.
3.3. Payment of Compensation . The Company will pay Executives Base Salary in accordance with the normal payroll cycle of the Company as established from time to time. All compensation paid to Executive will be subject to applicable taxes, withholding and other required, usual or elected employee deductions.
4. Termination of Agreement .
This Agreement and all obligations under this Agreement (except for obligations contained in Sections 4, 5 and 6, which will survive any termination of Executives employment or this Agreement) will terminate upon the earliest to occur of any of the following:
4.1. At-Will . Either Party may terminate Executives employment for any reason, with or without cause and without advance notice.
4.1.1. If Executive terminates employment pursuant to this Section, Executive will receive (a) Base Salary prorated through the last day of Executives actual employment; (b) any bonus, if earned pursuant to the requirements of Section 3; (c) accrued and unpaid vacation; (d) unreimbursed expenses pursuant to Section 3 (collectively, Separation Pay). Except to the extent required by law or Incentive Plan Document, all other obligations and liabilities of Company terminate as of the effective date of any such termination.
4.2. Death or Disability . This Agreement will terminate immediately upon the death of Executive or upon the determination that Executive cannot perform the fundamental duties of his position with or without accommodation. If this Agreement terminates for the death or disability of Executive, Executive or Executives representatives will receive Separation Pay. Except to the extent required by law or Incentive Plan Document, all other obligations and liabilities of Company terminate as of the effective date of any such termination.
4.3. Compliance with IRC Section 409A . Notwithstanding anything to the contrary in this Agreement, if any payment to be made pursuant to this Agreement will trigger any accelerated or additional tax under Section 409A, then Company will defer or modify the commencement or payments to prevent such accelerated or additional tax under Section 409A.
4.4. Resignation as Board Member or Officer . If applicable to Executive, immediately upon the termination of Executives employment with Company, Executive will tender a written notice of Executives resignation from any and all offices of the Company and all subsidiaries, affiliates or clients in which the Executive represents the Company in the capacity of an officer or director. Notwithstanding any failure by the Executive to provide the Company with written notice of resignation, Executive hereby authorizes and directs the Board of Directors to accept the Executives resignation from all positions effective as of the date of termination of the Executives employment.
5. Property Rights and Obligations of Executive . Executive agrees to be bound by the terms and conditions of Companys Employee Non-Disclosure and Invention Agreement, which is
3
CONFIDENTIAL
incorporated by reference and attached as an Exhibit A to this Agreement. The provisions of this Section 5 and Attachment A will survive the termination of this Agreement. The covenants in this Section 5 and Attachment A will be construed as separate covenants and to the extent any covenant will be judicially unenforceable, it will not affect the enforcement of any other covenant. In the event Executive breaches any of the provisions of this Section 5 and Attachment A, Executive agrees that Company will be entitled to injunctive relief in addition to any other remedy to which Company may be entitled.
6. General Provisions .
6.1. Notices . Any notices or other communications required or permitted to be given under this Agreement must be in writing and addressed to Company or Executive at the addresses below, or at such other address as either Party may from time to time designate in writing. Any notice or communication that is addressed as provided in this Section will be deemed given (a) upon delivery, if delivered personally or via certified mail, postage prepaid, return receipt requested; or (b) on the first business day of the receiving Party after the transmission if by facsimile or after the timely delivery to the courier, if delivered by overnight courier. Other methods of delivery will be acceptable only upon proof of receipt by the Party to whom notice is delivered.
|
If to Company: |
Osmetech Molecular Diagnostics, 757 S. Raymond Ave, Pasadena, Ca 91105 ATTN: Human Resources | |||
|
If to Executive: |
331 Ridgewood Ave, Glen Ellyn, IL 60137 | |||
6.2. Choice of Law and Forum . Except as expressly provided otherwise in this Agreement, this Agreement will be governed by and construed in accordance with the laws of the State of California. Both Parties agree that San Diego, California will be the venue of any proceeding and both Parties consent to the personal jurisdiction of the state and federal courts of the State of California.
6.3. Entire Agreement; Modification and Waiver . This Agreement supersedes any and all other agreements, whether oral or in writing, between the Parties with respect to the employment of Executive by Company and contains all covenants and agreements between the Parties relating to such employment in any manner whatsoever. Each Party to this Agreement acknowledges that no representations, inducements, promises, or agreements, oral or written, have been made by any Party, or anyone acting on behalf of any Party, that are not embodied herein, and that no other agreement, statement, or promise not contained in this Agreement will be valid or binding. Any modification of this Agreement will be effective only if it is in writing signed by the Party to be charged. No waiver of any of the provisions of this Agreement will be deemed, or will constitute, a waiver of any other provision, whether or not similar, nor will any waiver constitute a continuing waiver. No waiver will be binding unless executed in writing by the Party making the waiver.
6.4. Assignment . This Agreement may not be assigned in whole or in part by Executive without the prior written consent of Company. However, subject to the foregoing limitation, this Agreement will be binding on, and will inure to the benefit of, the Parties and their respective heirs, legatees, executors, administrators, legal representatives, successors and assigns.
4
CONFIDENTIAL
6.5. Severability . If for any reason whatsoever, any one or more of the provisions of this Agreement will be held or deemed to be inoperative, unenforceable, or invalid as applied to any particular case or in all cases, such circumstances will not have the effect of rendering any such provision inoperative, unenforceable, or invalid in any other case or of rendering any of the other provisions of this Agreement inoperative, unenforceable or invalid.
6.6. Representation by Counsel; Interpretation . Company and Executive acknowledge that each Party to this Agreement has had the opportunity to be represented by counsel in connection with this Agreement and the matters contemplated by this Agreement. Accordingly, any rule of law or decision which would require interpretation of any claimed ambiguities in this Agreement against the Party that drafted it has no application and is expressly waived. In addition, the term including and its variations are always used in the non-restrictive sense (as if followed by a phrase such as but not limited to). The provisions of this Agreement will be interpreted in a reasonable manner to affect the intent of the Parties.
6.7. Headings and Captions . Headings and captions are included for purposes of convenience only and are not a part of the Agreement.
6.8. Counterparts . This Agreement may be executed simultaneously in one or more counterparts, each of, which will be deemed an original, but all of which together will constitute one and the same instrument. Fax signatures will be valid and binding.
| OSMETECH MOLECULAR DIAGNOSTICS | ||
| By: |
/s/Jon Faiz Kayyem |
|
| Its: | Chief Executive Officer | |
| Date: | 3/10/10 | |
| Executive | ||
|
/s/Jeffrey A. Hawkins |
||
| Jeffrey A. Hawkins | ||
| Date: | 3/10/10 | |
5
CONFIDENTIAL
Attachment A to Executive Employment Agreement
Employee Non-Disclosure and Invention Agreement
This Executive Non-Disclosure and Invention Agreement (NDIA Agreement) is entered into as of the Effective Date of the Executive Employment Agreement (NDIA Agreement) Osmetech Molecular Diagnostics, a wholly owned subsidiary of Osmetech Technologies, Inc. (Company) and Jeffrey A. Hawkins (Executive). Company and Executive are each a Party to this NDIA Agreement and are sometimes collectively referred to as Parties.
Recitals Of The Intent Of The Parties
A. As an employee of the Company, Executive may receive or have access to business plans, inventions, discoveries, technical information, trade secrets, writings, designs, and other proprietary and confidential information of value and of such importance to the Company that it must be maintained as proprietary and confidential trade secrets of the Company both during and after termination of your employment. Furthermore, Executive may conceive or create Inventions (as defined below) in connection with and during the period of Executives employment with the Company.
B. This NDIA Agreement is attached to and incorporated into the Agreement pursuant to Section 5 of the Agreement. Execution of this NDIA Agreement is a condition of employment.
In consideration for the new or continued employment of Executive, and other valuable consideration, Company and Executive agree as follows:
1. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION . Executive recognizes that during the course of employment with Company, Executive may have access to Confidential Information of Company, its subsidiaries and other organizations controlled by, controlling, or under common control with it (Affiliates). Company Group means Osmetech, Inc. and its Affiliates, including Company. Company Group is a third-party beneficiary of this NDIA Agreement and the restrictive covenants in this NDIA Agreement are intended for the benefit of Company Group. As used in this NDIA Agreement, the term Confidential Information means the applicable information of each Company Group and includes information not publicly available about Company Groups: (a) research and development; manufacturing methods and formulas; (b) purchasing; marketing; sales costs; pricing inventions; improvements; (c) inventions, discoveries and ideas (whether patentable or not) related to their activities; (d) business and management development plans; (e) customer and supplier contact information and requirements; (f) proprietary software systems and technology related methodologies; (g) customers proprietary software systems and technology related methodologies; (h) activities of their established committees or boards; (i) litigation, disputes, or investigations to which they may be (or may have been) a party and legal advice provided to Executive in the course of Executives employment; and (j) any other trade secrets. Executive acknowledges and agrees that all rights, title and interest in any Confidential Information will remain the exclusive property of Company. Executive will not, without the written consent of the Chief Operating Officer, during the term employment or at any time after the termination of employment, disclose copy, make use of, or remove from Company premises, Confidential Information except as may be required in the course of Executives employment with and for the
6
CONFIDENTIAL
benefit of Company. Executive specifically acknowledges that any use of Confidential Information by persons not employed by Company or who are not authorized by Company to use the information provides such persons an unfair competitive advantage which they would not have had without the use of Confidential Information.
2. RETURN OF CONFIDENTIAL INFORMATION AND OTHER COMPANY PROPERTY . No later than Executives termination date, Executive will return to Company and delete from any personal computer or other device all originals and all copies of any Company property, Confidential Information, and all materials, documents, notes, manuals, computer disks, computers, or lists containing or embodying Confidential Information, or relating directly or indirectly to the business of Company, which are in Executives possession or control.
2.1. INVENTIONS AND ORIGINAL WORKS ASSIGNED TO Company. Executive agrees to make prompt written disclosure to Company, will hold in trust for the sole right and benefit of Company, and hereby assigns to Company all Executives right, title and interest in and to any ideas, inventions, discoveries, concepts and ideas, whether patentable or not, including but not limited to processes, methods, formulae, software, techniques, strains, cultures, and organisms, as well as improvements and know-how, concerning any present or planned activities of Company that Executive is aware of as a result of employment of Company, original works of authorship, developments, improvements or trade secrets which Executive may solely or jointly conceive or reduce to practice, or cause to be conceived or reduced to practice, during the period of Executives employment with Company. Executive recognizes that this NDIA Agreement does not require assignment of any invention, which qualifies for protection under Section 2870 of the California Labor Code. 1
3. In addition, Executive acknowledges that all original works of authorship which are made by Executive (solely or jointly with others) within the scope of employment and which are protectable by copyright are works made for hire, as that term is defined in the United States Copyright Act. Executive will assist to obtain and enforce United States and foreign proprietary rights relating to any and all inventions, original works of authorship, developments, improvements or trade secrets of Company.
4. INVENTIONS/ORIGINAL WORKS RETAINED BY EMPLOYEE . Below is a complete disclosure of all inventions, original works of authorship, developments, improvements, and trade secrets that he has, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of Executives employment with Company, that Executive considers to be the property of Executive or the property of third parties and that Executive wishes to have excluded from the scope of this NDIA Agreement: .
| 1 |
Section 2870 provides: (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employers equipment, supplies, facilities, or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to the employers business, or actual or demonstrably anticipated research or development of the employer; or (2) Result from any work performed by the employee for the employer. (b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable. |
7
CONFIDENTIAL
5. NOTICE TO THIRD PARTIES . In the event that Executives employment with Company terminates, Executive consents to the notification of Executives new employer or company of Executives rights and obligations under this NDIA Agreement.
6. OBLIGATIONS TO FORMER EMPLOYERS AND OTHER PARTIES . Executive promises that Executive has not brought to Company and will not improperly use or disclose any proprietary information or trade secret of former employers or companies. Executive also represents that Executives employment under this NDIA Agreement does not breach any other agreement or obligation of Executive and that Executive has not entered into any written or oral agreement in conflict with this NDIA Agreement.
7. NON-SOLICITATION OF COMPANY EMPLOYEES. Executive recognizes that Companys employees are a valuable resource of Company. Executive will not during the term of Executives employment and for a period of one (1) year following its termination, either alone or in conjunction with any other person or entity, directly or indirectly solicit, induce, recruit, aid or suggest to any Company Executive to leave the employ of Company, or terminate or violate any contractual or fiduciary duty owing to Company.
8. RESTRICTIONS ON COMPETITION DURING EMPLOYMENT . Executive agrees that during Executives employment with Company Executive will not, directly or indirectly, have any ownership interest, work for advise, or have any business relationship with any person or entity that competes with Company, or that is planning to compete with Company, without the prior written approval of a manager who is at least at the Vice President level. While employed by Company, Executive will not use any unfair business practices to establish a competing business or undertake any actions to impair Companys relationship with its existing customers and business.
9. NON-SOLICITATION OF CUSTOMERS USING CONFIDENTIAL INFORMATION . Executive recognizes that information about Companys customers are Confidential Information and trade secrets of Company. During the term of Executives employment and for a period of one (1) year following its termination, Executive will not use Confidential Information or other unfair business practices to divert or attempt to divert from Company any business or customers with whom Executive dealt or about whom Executive had access to Confidential Information by virtue of Executives employment.
10. SURVIVAL OF OBLIGATION . Executive expressly understands and agrees that the obligations, responsibilities and duties of Executive under this NDIA Agreement will survive the termination of Executives employment with Company.
11. NOTICE OF LEGAL OBLIGATION . In the event that Executive is required in a civil, criminal or regulatory proceeding to disclose any part of the Confidential Information, Executive will give the President of Company prompt written notice of the request to permit Company to seek an appropriate remedy or to waive the Executives compliance with the provisions of this NDIA Agreement in regard to the request.
12. NOTICE OF UNAUTHORIZED DISCLOSURE . If Executive loses or makes unauthorized disclosure of any of the Confidential Information, the Executive will immediately notify Company take all reasonable steps necessary to retrieve the lost or improperly disclosed Confidential Information.
8
CONFIDENTIAL
13. EMPLOYMENT AT-WILL . Nothing in this NDIA Agreement is intended to change the at-will status of Executives employment with Company and Executive understands that Company or Executive may terminate the employment relationship with or without cause and with or without advance notice.
14. REMEDIES . The parties recognize that a breach of this NDIA Agreement by Executive will cause an irreparable injury to Company that cannot be reasonably or adequately compensated for in money damages. In the event of any breach or threatened breach, Company will be entitled, in addition to any other remedies and damages available, to an injunction to restrain such breach or threatened breach by Executive, Executives partners, co-employees, agents, employers and employees, and any other persons acting or with Executive. Company will be entitled to injunctive relief for the duration specified in the applicable paragraph(s) of the NDIA Agreement, commencing from the date such relief is granted, but reduced by the period of time elapsed between Executives termination date and Executives first breach or threatened breach of this NDIA Agreement.
15. ASSIGNMENT . This NDIA Agreement will be binding upon and inure to the benefit of Company, its successors and assigns, and to the benefit of Executive, Executives heirs and legal representatives. Executive agrees that this NDIA Agreement may be assigned by Company to any successor or other party, without the consent of Executive. The transfer of Executive to any other Company corporate parent, affiliate, subsidiary, or successor will constitute an assignment of this NDIA Agreement.
16. CONTROLLING LAW AND JURISDICTION . This NDIA Agreement will be governed by, construed by, and enforced in accordance with the laws of the State of California without regard to conflict of law provisions. Executive specifically consents to personal jurisdiction in the State of California.
17. SEVERABILITY . If any provision, paragraph or subparagraph in this NDIA Agreement is adjudged by any court to be void or unenforceable in whole or in part, this adjudication will not affect the validity of the remainder of the NDIA Agreement. Each provision, paragraph and subparagraph of this NDIA Agreement is separable and constitutes a separate and distinct covenant. The parties further expressly agree that if any provision is susceptible to two or more constructions, one of which would render the provision unenforceable, then the provision will be construed to have the meaning that renders it enforceable.
18. HEADINGS AND INTERPRETATION . Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this NDIA Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa. The term including and its variations are always used in the non-restrictive sense as if followed by a phrase such as but not limited to. Executive and Company agree that any ambiguity in the terms of this NDIA Agreement will not be construed against any of the parties and any rule of law or decision that would require interpretation of any claimed ambiguities in this NDIA Agreement against the party that drafted it is expressly waived. The provisions of this NDIA Agreement will be interpreted in a reasonable manner to affect the intent of the parties.
19. AMENDMENT AND NONWAIVER . This NDIA Agreement may only be amended or modified by a written instrument executed by both Company and Executive. The failure by Company to enforce any provision of this NDIA Agreement will not be deemed a waiver of such provision or of Companys right to enforce each and every provision of this NDIA Agreement, or agreements signed by other employees. Any such failure will not operate or be construed as a waiver of any subsequent breach by Executive.
9
CONFIDENTIAL
20. COUNTERPARTS . This NDIA Agreement may be executed in counterparts and a faxed signature will be valid.
21. ENTIRE AGREEMENT . This NDIA Agreement constitutes the entire agreement of the parties with respect to the subject matter of the NDIA Agreement and supersedes and replaces any previous communications, representations, arrangements or agreements, whether oral or written, addressing the terms, conditions, and issues contained in the NDIA Agreement.
| OSMETECH MOLECULAR DIAGNOSTICS | ||
| By: |
/s/Jon Faiz Kayyem |
|
| Its: | Chief Executive Officer | |
| Date: | 3/10/10 | |
| Executive | ||
|
/s/Jeffrey A. Hawkins |
||
| Jeffrey A. Hawkins | ||
| Date: | 3/10/10 | |
10
CONFIDENTIAL
Exhibit 10.33
EXECUTIVE CONSULTING AGREEMENT
THIS EXECUTIVE CONSULTING AGREEMENT (this Agreement ), dated as of October 12, 2010, (the Effective Date ) is entered into by and between GenMark Diagnostics, Inc. (the Company ), and Kuranda Partners LLC ( Consultant ).
RECITAL
The Company wishes to engage Consultant to provide consulting services on the terms set forth on attached Exhibit A , and Consultant is willing to provide such services on such terms.
NOW, THEREFORE, IT IS AGREED:
1. Duties and Services . Consultant shall provide such consulting services as described on Exhibit A , and such other services as may be mutually agreed upon by the parties from time to time (the Services ). Performance of the Services shall be governed by the terms and conditions of this Agreement.
2. Term and Termination . This Agreement shall be for a term commencing on August 12, 2010 and continuing until July 30, 2011, unless sooner terminated by written notice from one party to the other.
3. Compensation . As compensation for the Services to be provided hereunder, and conditioned upon Consultants performance of such services, Consultant shall be entitled to fees as set forth on Exhibit B .
4. Independent Contractor . Consultants relationship with the Company is that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship. Accordingly, Consultant will not be entitled to any of the benefits that Company may make available to its employees; and Consultant is solely responsible for, and will file, on a timely basis, all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of services and receipt of fees under this Agreement.
5. Inventions .
(a) Company Inventions . All designs, artwork, improvements, inventions, works of authorship, information fixed in any tangible medium of expression, moral rights, trademarks, know-how, ideas, and all other subject matter protectable under patent, copyright moral right, mask work, trademark, trade secret or other laws ( Inventions ), made, conceived or developed by Consultant, alone or with others, which result from the Services or any other services provided by Consultant from the first day of engagement by the Company, together with all related intellectual property rights, shall be the sole property of the Company ( Company Inventions ).
(b) Out-of-Scope Inventions . If Consultant incorporates any Inventions relating in any way to the Companys business or demonstrably anticipated research or development that were conceived, reduced to practice, created, derived, developed or made by Consultant either outside the scope of Consultants Services for the Company under this Agreement or prior to the execution of this Agreement (collectively, the Out-of-Scope Inventions ) into any of the Company Inventions, Consultant hereby grants to the Company a royalty-free, irrevocable, worldwide, fully paid-up license (with rights to sublicense through multiple tiers of sublicensees) to practice all applicable patent, copyright, moral right,
mask work, trade secret and other intellectual property rights relating to any Out-of-Scope Inventions that Consultant incorporates, or permits to be incorporated, in any Company Inventions. Consultant agrees that Consultant will not incorporate, or permit to be incorporated, any Inventions conceived, reduced to practice, created, derived, developed or made by others or any Out-of-Scope Inventions into any Company Inventions without the Companys prior written consent.
(c) Assignment, Disclosure and Assistance . Consultant agrees to promptly disclose to the Company every Company Invention. Consultant hereby assigns and agrees to assign to the Company or its designee its entire right, title and interest worldwide in all such Company Inventions and any associated intellectual property rights. Consultant agrees to assist the Company in any reasonable manner to obtain and enforce for the Companys benefit patents, copyrights, maskworks, and other property rights in such Company Inventions in any and all countries, and Consultant agrees to execute, when requested, patent, copyright or similar applications and assignments to the Company and any other lawful documents deemed necessary by the Company to carry out the purpose of this Agreement.
6. Confidential Information .
(a) Definition of Confidential Information . Confidential Information as used in this Agreement shall mean all technical and non-technical information including copyright, trade secret, and proprietary information, including, without limitation, customer data, customer information, information related to the current, future and proposed products and services, financial information, procurement requirements, purchasing information, manufacturing information, business forecasts, sales and merchandising and marketing plans and all other information of the Company. Confidential Information also includes proprietary or confidential information of any third party who may disclose such information to the Company or Consultant in the course of the Companys business.
(b) Nondisclosure and Nonuse Obligations . Except as permitted in this paragraph, Consultant shall not use, disclose or disseminate any Confidential Information of the Company. Consultant may use the Confidential Information of the Company solely to perform its obligations under this Agreement for the benefit of the Company. Consultant will exercise the same degree of care as it takes to protect its own confidential information, but in no event less than reasonable care.
(c) Injunctive Relief . It is understood and agreed that money damages would not be a sufficient remedy for a breach of Consultants confidentiality obligations under this Agreement and that the Company shall be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to be the exclusive remedy for the breach of Consultants obligations under this Section 6(c), but will be in addition to all other available legal or equitable remedies.
(d) Exclusions from Nondisclosure and Nonuse Obligations . Consultants obligations under this Section 6 with respect to any portion of the Confidential Information of the Company shall not apply to any such portion that Consultant can demonstrate (i) was in the public domain at or subsequent to the time such portion was communicated to Consultant by the Company through no fault of Consultant, or (ii) was rightfully in Consultants possession free of any obligation of confidence at or subsequent to the time such portion was communicated to Consultant by the Company. A disclosure of Confidential Information by Consultant either in response to a valid order by a court or other governmental body, otherwise required by law, or necessary to establish the rights of either party under this Agreement shall not be considered a breach of this Agreement or a waiver of confidentiality for other purposes, provided , however , that Consultant shall provide prompt prior written notice thereof to the Company to enable the Company to seek a protective order or otherwise prevent such disclosure.
2
7. Ownership and Return of Company Property . All materials furnished to Consultant by the Company, whether delivered to Consultant by the Company or made by Consultant in the performance of services under this Agreement (collectively, the Company Property ) are the sole and exclusive property of the Company, and Consultant hereby does and will assign to the Company all rights, title and interest Consultant may have or acquire in the Company Property. At the Companys request and no later than five (5) days after such request, Consultant shall, at the Companys option, destroy or deliver to the Company (i) all Company Property, (ii) all tangible media of expression in Consultants possession or control that incorporate or in which are fixed any Confidential Information of the Company, and (iii) written certification of Consultants compliance with Consultants obligations under this Agreement.
8. No Violation of Third Party Rights . Consultant shall not communicate any information to the Company in violation of the proprietary rights of third parties.
9. Warranty . Consultant shall perform the Services under this Agreement in a workmanlike and commercially reasonable manner, with a standard of diligence and care normally employed by qualified persons in the performance of comparable work in the same or similar locality. Consultant shall devote sufficient effort and resources to the performance of the Services and shall be responsive to the Companys reasonable needs and requests in so doing. Consultant warrants that there is no other contract or duty on Consultants part that conflicts with or is inconsistent with this Agreement. Consultant will comply with all applicable specifications, laws, ordinances, rules, regulations, orders, licenses, permits and other contractual or governmental requirements.
10. Miscellaneous .
(a) Successors and Assigns . Consultant may not subcontract or otherwise delegate Consultants obligations under this Agreement without the Companys prior written consent. Subject to the foregoing, this Agreement will be for the benefit of the Companys successors and assigns, and will be binding on Consultants assignees.
(b) Notices . Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows, with notice deemed given as indicated: (a) by personal delivery, when delivered personally; (b) by overnight courier, upon written verification of receipt; (c) by telecopy or facsimile transmission, upon acknowledgement of receipt of electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth in this Agreement or to such other address as either party may specify in writing.
(c) Governing Law . This Agreement shall be governed in all respects by the laws of the state of California, without giving effect to conflicts of law principles. Venue for any dispute arising under this Agreement will lie exclusively in the state or federal courts located in the County of San Diego of the state of California.
(d) Severability . If any provision of this Agreement is held by a court of law to be illegal, invalid or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the same economic effect as the original provision, and the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.
(e) Entire Agreement . This Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof, and is not intended to confer upon any party other than the parties hereto any rights or remedies hereunder.
3
(f) Waiver; Amendment; Modification . No term or provision hereof will be considered waived by the Company, and no breach excused by the Company, unless such waiver or consent is in writing signed by the Company. Any such waiver by the Company of, or consent by the Company to, a breach of any provision of this Agreement by Consultant, shall not operate or be construed as a waiver of, consent to, or excuse of any other or subsequent breach by Consultant. This Agreement may be amended or modified only by mutual agreement of duly authorized representatives of the parties in writing.
(g) Survival . The rights and obligations contained in this Agreement, which by their nature require performance following termination, shall survive any termination or expiration of this Agreement.
(h) Counterparts . This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one instrument.
[ signature page follows ]
4
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the Effective Date.
|
CONSULTANT
|
||||||||
|
KURANDA PARTNERS LLC
|
||||||||
| Dated: | 10/12/2010 | By: |
/s/ Christopher Gleeson |
|||||
| Christopher Gleeson | ||||||||
|
COMPANY
|
||||||||
|
GENMARK DIAGNOSTICS, INC.
|
||||||||
|
Dated: |
10/12/10 | By: |
/s/ Jennifer Williams |
|||||
| Name: Jennifer Williams | ||||||||
| Title: SVP, Ops, Quality, HR | ||||||||
EXHIBIT A
Consulting Services
Consultant shall cause Christopher Gleeson to serve as the Companys interim Chief Executive Officer. Subject to the supervisory powers of the Board of Directors, Mr. Gleeson shall perform such duties as shall be reasonably assigned to him by the Board of Directors, consistent with the expectations set forth in the Executive Consulting Agreement (including the exhibits thereto). Mr. Gleeson shall have general charge of the business and affairs of the Company. Mr. Gleeson shall keep the Board of Directors fully informed with respect to his duties and shall freely consult with them concerning the business of the Company. Mr. Gleeson shall perform all the functions and all such duties as are customarily incident to his role as interim Chief Executive Officer. Mr. Gleeson may sign, with the Secretary or any other officer of the corporation thereunto authorized by the Board of Directors, certificates for shares of the corporation, any deeds, mortgages, bonds, contracts, or other instruments that the Board of Directors has authorized to be executed, except in cases where the signing and execution thereof shall be expressly delegated by the Board of Directors or by the Companys Bylaws to some other officer or agent of the Company, or shall be required by law to be otherwise signed or executed; and in general shall perform all duties incident to the office of Chief Executive Officer and such other duties as may be prescribed by the Board of Directors from time to time.
The Company anticipates that Mr. Gleeson will perform his services principally from the Companys headquarters located in Carlsbad, California.
6
EXHIBIT B
Payment of Fees
The parties agree that fees for the Services and any subsequently agreed upon Services to be provided shall be paid to Consultant as follows:
1. Cash Compensation . There will be no cash compensation paid for the performance by Mr. Gleeson of the Services.
2. Equity Compensation . Mr. Gleeson has been granted 109,375 shares of Company restricted common stock under the Companys 2010 Equity Incentive Plan (the Plan), which shall vest in two equal tranches (a) the first tranche of 54,687.5 shares shall vest on January 30, 2011, and (b) the second tranche of 54,87.5 shares shall vest on July 30, 2011. In the event the Company terminate this agreement without Cause as defined below, prior to July 30, 2011, all 109,375 shares will fully vest on the termination date. If Mr. Gleeson is terminated with Cause, or resigns before July 30, 2011, Mr. Gleeson shall not be entitled to retain any Company stock contemplated by this paragraph other than the shares which have vested as of the date of Mr. Gleesons termination.
3. Temporary Housing Benefit . To assist in providing temporary housing in Carlsbad while Mr. Gleeson performs the duties required by this Agreement, and subject to Mr. Gleesons continued provision of the Services and the satisfactory performance of the duties referenced on Exhibit A, Company agrees to provide Mr. Gleeson reimbursement for temporary housing at a rate not to exceed $5,000.00 per month for the period from August 9, 2010 to July 30, 2011, or such earlier time at which Mr. Gleeson no longer serves as the Companys interim Chief Executive Officer. In order to obtain reimbursement for temporary housing, Mr. Gleeson will be required to submit a monthly expense report, with appropriate receipts. The Company does not make any representations regarding the tax consequences of this benefit and Mr. Gleeson is advised to obtain Mr. Gleesons own tax counsel for such information and guidance.
4. Definition of Cause . For purposes of this Agreement, Cause is defined as: (a) acts or omissions constituting gross negligence, recklessness or willful misconduct on the part of Mr. Gleeson with respect to Mr. Gleesons obligations or otherwise relating to the business of Company; (b) any acts or conduct by Mr. Gleeson that are materially adverse to Companys interests; (c) Mr. Gleesons material breach of this Agreement; (d) Mr. Gleesons breach of Companys Employee Innovations and Proprietary Rights Agreement; (e) Mr. Gleesons conviction or entry of a plea of nolo contendere for fraud, misappropriation or embezzlement, or any felony or crime of moral turpitude or that otherwise negatively impacts Mr. Gleesons ability to effectively perform his duties hereunder; or (f) Mr. Gleesons willful neglect of duties as determined in the sole and exclusive discretion of the Board of Directors.
7
Exhibit 10.34
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement (Agreement), dated as of April 5, 2011 (the Execution Date), is made by and between GenMark Diagnostics, Inc. (Company) and Hany Massarany (Executive).
The parties agree as follows:
1. Employment/Start Date . Executives employment shall commence on a date determined by Executive (Start Date) which shall be no later than four weeks following the Execution Date. As of the Start Date, Company hereby employs Executive, and Executive hereby accepts such employment, upon the terms and conditions set forth herein. It is noted, that while Executive will perform the tasks contemplated hereby on behalf of the Company, he will be employed by the Companys wholly-owned operating subsidiary, Clinical Microsensors, Inc. Between the Execution Date and the Start Date, Executive shall provide services to the Company, up to a maximum of 20 hours per week, as a consultant.
| 2. | Duties . |
2.1 Position . Commencing on the Start Date, Executive is employed as President and Chief Executive Officer and shall have the duties and responsibilities assigned by Companys Board of Directors (Board of Directors) both upon initial hire and as may be reasonably assigned from time to time and shall report directly to the Board of Directors. Notwithstanding the foregoing, Executive shall have such authority, power, responsibilities and duties as are inherent in his positions (and the undertakings applicable to his positions) and necessary to carry out his responsibilities and the duties required of him hereunder. The Board of Directors reserves the right to modify Executives duties at any time in its sole and absolute discretion; provided , however , that Executive shall not, without his consent, be assigned duties that would be inconsistent with those of a chief executive officer of a comparable company to the Company. In addition, Executive shall be elected to serve as a member of Companys Board of Directors during Executives employment with Company.
2.2 Full-time . Commencing on the Start Date, Executive agrees that he shall perform his duties faithfully and efficiently and to the best of his abilities, subject to the directions of the Board of Directors. Executive shall devote Executives full business time and efforts to the performance of Executives assigned duties for Company, unless Executive notifies the Board of Directors in advance of Executives intent to engage in other paid work and receives the Board of Directors express written consent to do so. Notwithstanding the foregoing, during his employment, Executive may devote reasonable time to the supervision of his personal investments and activities involving professional, charitable, community, educational, religious and similar types of organizations, speaking engagements, membership on the boards of directors of other organizations, and similar types of activities, to the extent that such other activities do not interfere with the performance of Executives duties under this Agreement, are not competitive with the Company, do not violate the provisions of section 9 below or otherwise conflict in any material way with the business of the Company ; provided , however , that Executive shall not serve on the board of directors of any business, or hold any other position with any business, without the prior consent of the Board of Directors, which consent shall not be unreasonably withheld or delayed.
1
2.3 Work Location . Executives principal place of work shall be located in Carlsbad, California.
3. At-Will Employment . Executives employment with Company is at-will and not for any specified period and may be terminated at any time, with or without Cause (as defined below) or advance notice, by either Executive or Company subject to the provisions regarding termination set forth below in section 8. No representative of Company, other than the Board of Directors, has the authority to alter the at-will employment relationship. Any change to the at-will employment relationship must be by specific, written agreement, authorized by the Board of Directors. Nothing in this Agreement is intended to or should be construed to contradict, modify or alter this at-will relationship.
4. Compensation .
4.1 Base Salary . Commencing on the Execution Date, as compensation for Executives performance of Executives duties hereunder, Company shall pay to Executive an initial Base Salary of Four Hundred Fifty Thousand Dollars ($450,000) per year payable in accordance with the normal payroll practices of Company, less required deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. In the event Executives employment under this Agreement is terminated by either party, for any reason, Executive will earn the Base Salary prorated to the date of termination. The Base Salary shall be reviewed for increases by the Board of Directors in good faith, based upon Executives performance, not less often than annually. The term Base Salary shall refer to the Base Salary as so increased by the Board of Directors.
4.2 Incentive Compensation . Executive will be eligible to participate in Companys performance incentive compensation bonus program (the Annual Bonus Program) with a target annual bonus equal to 75% of Executives Base Salary for 2011 and 100% of Executives Base Salary in subsequent years (Target). The Annual Bonus Program shall provide that Executive may earn up to a maximum of 150% of the Target then in effect based on exceeding the objectives or milestones established by the Compensation Committee of the Board of Directors (the Compensation Committee). For calendar year 2011, Executive will be guaranteed a minimum bonus equal to a pro rata portion of 50% of Executives Target calculated based on the portion of the calendar year during which Executive performs services for the Company following the Execution Date (the 2011 Guaranteed Bonus). Except with respect to the portion of the 2011 annual bonus that represents the 2011 Guaranteed Bonus, the actual amount of the annual bonus earned by and payable to Executive in any year shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee and communicated to Executive, and shall be subject to such other terms and conditions of the Companys Annual Bonus Program as in effect from time to time. Each bonus paid under the Annual Bonus Program shall be paid to Executive no later than March 15th of the calendar year following the calendar year in which the bonus is earned.
2
4.3 Equity Grants . On the Execution Date, Executive shall be granted (i) a non-qualified stock option to purchase 275,000 shares of Companys Common Stock, par value $0.0001 per share (the Common Stock), at a per share exercise price equal to the fair market value of a share of Common Stock on the date of the grant (the Option), on the terms and conditions set forth in this Agreement, the Companys 2010 Equity Incentive Plan (the Plan) and the corresponding Option Agreement by and between Company and Executive (the Option Agreement), in the form attached hereto as Exhibit A and (ii) a restricted stock award of 176,739 shares of the Companys Common Stock, par value $0.0001 (the Restricted Stock), on the terms and conditions set forth in this Agreement, the Plan and the corresponding Restricted Stock Purchase Agreement by and between the Company and Executive (the Purchase Agreement), in the form attached hereto as Exhibit B . The terms of the Option Agreement and the Purchase Agreement shall take precedence over any conflicting terms in the Plan. In the event of a Change in Control (as defined in the Plan), the Option, the Restricted Stock and all future options and shares of restricted stock granted to Executive by Company shall immediately vest in full and, in a transaction pursuant to which the shareholders of Company receive cash consideration, Executive shall surrender Executives options to Company and shall receive a cash payment in an amount equal to the number of shares of Common Stock then subject to the options multiplied by the excess, if any, of the fair market value of a share of Common Stock as of the date of the Change in Control, over the exercise price per share of the Common Stock subject to the options.
4.4 Performance and Salary Review . The Board of Directors will periodically review Executives performance on no less than an annual basis. Adjustments to Base Salary or other compensation, if any, will be made by the Board of Directors in its sole and absolute discretion; provided , however , that Executives Base Salary and Target shall not be reduced from the levels set forth in this Agreement or the levels established by the Board of Directors through future increases in Executives Base Salary and Target.
5. Other Benefits .
5.1 Savings and Retirement Plans . Commencing on the Start Date, Executive shall be entitled to participate in all qualified and non-qualified savings and retirement plans applicable generally to other executives of Company, in accordance with the terms of the plans, as may be amended from time to time.
5.2 Welfare Benefit Plans . Commencing on the Start Date, Executive and/or his eligible dependents shall be eligible to participate in and shall receive all benefits under the Companys welfare benefit plans and programs applicable generally to other executives of Company, in accordance with the terms of the plans, as may be amended from time to time.
5.3 Vacation . Executive shall be entitled to paid vacation time consistent with the applicable policies of Company as in effect from time to time, but in any event no less than four weeks of such vacation per year.
5.4 Fringe Benefits . Executive shall be entitled to such fringe benefits as may be available generally to other executives of Company.
3
5.5 Unpaid Retention Bonus . If Executives employer from his immediately preceding employment fails to pay all or any portion of the final retention payment due to Executive in April 2011, then the Company shall reimburse Executive for any unpaid amount up to a total of $250,000, in two equal cash payments, the first made on May 31, 2011 and the other made on November 30, 2011.
6. Business Expenses . Subject to subsection 8.8(c), Executive will be reimbursed for all business-related travel and other expenses incurred in the performance of Executives duties on behalf of Company in accordance with Companys policies. To obtain reimbursement, expenses must be submitted promptly with appropriate supporting documentation and will be reimbursed in accordance with Companys policies.
7. Relocation Benefit . In exchange for Executive agreeing to relocate Executives primary residence to San Diego County, California on or before April 30, 2012, and performing the duties referenced in subsection 2.1 above, Company will provide Executive with a relocation benefit. This will include the Companys direct payment for house hunting trips for Executive and Executives immediate family, the moving of household goods and automobiles, closing and finance costs actually incurred for the purchase of Executives primary residence in San Diego County, California, and closing and commission costs actually incurred for the sale of Executives existing home in Tucson, Arizona, and from Executives Start Date through August 31, 2011, a temporary housing allowance of up to $5,000 per month and reasonable commuting costs between Tucson, Arizona and San Diego County, California (Relocation Benefits). Company may require supporting documentation from Executive prior to providing the above Relocation Benefits. The Relocation Benefits provided by Company, other than expenses for moving household goods and personal effects from Executives former residence to his new residence, will be included in Executives gross income and subject to required deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. Company does not make any representations regarding the tax consequences of this benefit and Executive is advised to obtain Executives own tax counsel for such information and guidance.
8. Termination of Executives Employment .
8.1 Termination Due to Death or Disability . Executives employment with the Company shall terminate automatically on Executives death. In the event of Executives Disability, as defined below, Company shall be entitled to terminate his employment. In the event of termination of Executives employment by reason of Executives death or Disability, Company shall pay to Executive (or his estate, as applicable), within 10 business days after Executives termination of employment or death, as the case may be, Executives Base Salary then in effect, prorated to the date of termination, and any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of Company (collectively, the Accrued Benefits ). In addition, Executive shall receive a bonus pursuant to subsection 4.2 for the fiscal year in which the termination of employment or death, as applicable, occurs based on actual performance for such full fiscal year under the Annual Bonus Program, determined solely by the achievement of those corporate financial goals and objectives established for the officers of the Company, including Executive (and not upon the achievement of any additional operating, strategic or other goals or objectives established only for Executive,
4
and without the exercise of any negative discretion), multiplied by a fraction, the numerator of which is the number of days that Executive was employed by Company during such fiscal year, and the denominator of which is 365. Such prorated bonus shall be payable at the time that bonuses are payable to officers of Company generally for such fiscal year (and not later than March 15 following the year in which the termination of employment occurs). Upon Executives termination of employment by reason of death or Disability, all outstanding Company equity awards, including but not limited to the Option and the Restricted Stock, shall vest and, in the case of stock options, become exercisable on the date of termination and, in the case of stock options, remain exercisable until the expiration date of such option. For purposes of this Agreement, Disability means a physical or mental disability or infirmity of Executive that prevents the normal performance of substantially all his duties for a period in excess of 90 consecutive days or for more than 180 days in any consecutive 12-month period. The payments contemplated by this Section 8.1 to be made in the event of termination of Executives employment by reason of Executives death or Disability shall be made in lieu of any other payments contemplated to be made to Executive pursuant to any section of this Agreement and all other Company obligations to Executive pursuant to this Agreement will become automatically terminated and completely extinguished.
8.2 Termination for Cause by Company . Although Company anticipates a mutually rewarding employment relationship with Executive, Company may terminate Executives employment immediately at any time for Cause. For purposes of this Agreement, Cause is defined as: (a) any act or omission that constitutes a material breach by Executive of any of his material obligations under this Agreement or the Employee Innovations and Proprietary Rights Agreement (in the form attached hereto as Exhibit C ), after a written demand for substantial performance is delivered to Executive by the Board of Directors that specifically identifies the manner in which the Board of Directors believes that Executive has materially breached such obligations and Executives failure to cure such alleged breach not later than 30 days following his receipt of such notice; (b) Executives conviction of, or plea of nolo contendere to, any felony; (c) Executives ongoing willful refusal to follow the proper and lawful directions of the Board of Directors after a written demand for substantial performance is delivered to Executive by the Board of Directors that specifically identifies the manner in which the Board of Directors believes that Executive has refused to follow its instructions and Executives failure to cure such refusal not later than 30 days following his receipt of such notice; or (d) any acts or omissions constituting willful misconduct by Executive (including any violation of federal securities laws) which is materially and demonstrably injurious to the financial condition or business reputation of Company and its subsidiaries, taken as a whole. For purposes of this subsection 8.2, no act, or failure to act, on the part of Executive shall be considered willful unless it is done, or omitted to be done, by Executive in bad faith or without reasonable belief that Executives action or omission was in the best interests of Company. Any act, or failure to act, based upon (i) authority given pursuant to a resolution duly adopted by the Board of Directors or (ii) the advice of counsel for Company shall be conclusively presumed to be done, or omitted to be done, by Executive in good faith and in the best interests of Company. In the event Executives employment is terminated in accordance with this subsection 8.2, Executive shall be entitled to receive the Accrued Benefits. All other Company obligations to Executive pursuant to this Agreement will become automatically terminated and completely extinguished. Executive will not be entitled to receive the benefits described in subsections 8.3 and 8.4 below.
5
8.3 Termination Without Cause by Company or by Executive for Good Reason/Severance .
(a) Company may terminate Executives employment under this Agreement without Cause at any time on thirty (30) days advance written notice to Executive. If (i) Executive provides written notice to Company of the occurrence of Good Reason event (as defined below) within 90 days after Executive has knowledge of the circumstances constituting Good Reason, which notice shall specifically identify the circumstances which Executive believes constitute Good Reason, (ii) Company fails to correct the circumstances constituting Good Reason within 30 days after such notice; and (iii) Executive resigns within six months after the initial existence of such circumstances; then Executives termination of employment shall constitute a resignation for Good Reason. In the event of Companys termination without Cause or Executives resignation for Good Reason, Executive will receive (i) the Accrued Benefits and (ii) the sum of (A) the Base Salary at the time of termination plus (B) the last annual bonus actually paid to Executive prior to such termination (the Severance Payment). Subject to Section 8.8, such Separation Payment shall be paid in a lump sum payment on the sixtieth day following the termination date. In addition, (i) all outstanding Company equity awards, including but not limited to the Option and the Restricted Shares, shall vest and, in the case of stock options, become exercisable on the date of termination and, in the case of stock options, remain exercisable until the expiration date of such option and (ii) during the one-year period commencing on the date of termination of employment, Company shall reimburse Executive for a portion of any premium payments made in order to continue his group health insurance pursuant to the terms of the Consolidated Omnibus Budget Reconciliation Act (COBRA) such that the health insurance provided under COBRA during such one-year period shall have the same after-tax cost to Executive and/or Executives family, as Executive would have been required to pay pursuant to the Companys plans, programs, practices and policies providing health care had Executives employment continued under this Agreement for such period (Healthcare Continuation Coverage). Notwithstanding the foregoing, if Executive becomes re-employed with another employer and is eligible to receive health care benefits under another employer-provided plan, the reimbursement provided hereunder shall cease. Executive will only receive the Severance Payment if Executive: (i) complies with all surviving provisions of this Agreement as specified in subsection 12.8 below; (ii) executes a full general release in a form attached hereto as Exhibit D , releasing all claims, known or unknown, that Executive may have against Company arising out of or in any way related to Executives employment or termination of employment with Company which release shall contain a provision that provides that neither Executive nor Company will make any voluntary statements, written or oral, or cause or encourage others to make any such statements that defame, disparage or in any way criticize the personal and/or business reputations, practices or conduct of the other, and such release has become effective in accordance with its terms prior to the 60th day following the termination date; and (iii) agrees to cooperate with pending litigation during the one-year severance period, subject to reimbursement of reasonable out-of-pocket travel costs and expenses.
(b) For purposes of this Agreement, resignation for Good Reason shall mean termination of employment by Executive because of the occurrence of any of the following events, without Executives prior written consent: (A) a material breach of this Agreement by Company (including but not limited to a removal of Executive from the office of Chief Executive Officer for a reason other than Cause or Disability); (B) Executives failure to
6
be elected or reelected to the Board of Directors; (C) a material diminution in Executives then authority, duties or responsibilities; (D) a reduction by Company in Executives Base Salary or Target; or (E) relocation of Executives base office to an office that is more than 30 highway miles from Executives base office prior to such relocation.
8.4 Change in Control Severance .
(a) In the event Executives employment is terminated without Cause (other than pursuant to Section 8.1) or Executive resigns for Good Reason within six months preceding or 24-months following a Change in Control (as defined in the Plan) then in lieu of the payments and benefits contemplated by Section 8.3, Executive shall be entitled to receive (i) the Accrued Benefits, (ii) the product of 2 multiplied by the sum of (A) Base Salary at the time of termination plus (B) the last annual bonus actually paid to Executive prior to such termination (the Change in Control Severance Payment), (iii) Healthcare Continuation Coverage for the 24-month period following such termination of employment, and (iv) all outstanding Company equity awards shall vest and, in the case of stock options, become exercisable on the date of termination and, in the case of stock options, remain exercisable until the expiration date of such option. In the event that Executives employment shall be terminated by Company without Cause (other than pursuant to Section 8.1) or by Executive for Good Reason within six months preceding a Change in Control, Executives Change in Control Severance Payment shall be reduced by any Severance Payments paid to Executive pursuant to Section 8.3. Subject to Section 8.8, Company (or the successor thereto) shall pay the Change in Control Severance Payment to Executive in a lump sum on the sixtieth day following the Change in Control (in the case of Executives termination of employment within six-months preceding a Change in Control) or termination of employment (in the case of Executives termination of employment within 24-months following a Change in Control).
(b) For purposes of this subsection 8.4, the term Good Reason shall have the same meaning as such term is defined in subsection 8.3 with the following modifications: (i) failure of Company to obtain a satisfactory agreement from any successor to assume and agree to perform this Agreement and (ii) upon or within 24 months following a Change in Control, either (A) Executive is not the chief executive officer of the publicly-traded entity resulting from such Change in Control or of the publicly-traded parent of such entity, in either case reporting directly to the board of directors of such publicly-traded entity or such publicly-traded parent, or (B) there is no publicly-traded entity resulting from such Change in Control and no publicly-traded parent of such entity.
8.5 Voluntary Resignation by Executive . Executive may voluntarily resign Executives position with Company, at any time on thirty (30) days advance written notice. In the event of Executives resignation, Executive will be entitled to receive Executives Base Salary and benefits for the thirty-day notice period and the Accrued Benefits. All other Company obligations to Executive pursuant to this Agreement will become automatically terminated and completely extinguished. In addition, Executive will not be entitled to receive the benefits described in Sections 8.3 and 8.4 above.
8.6 Pay in Lieu of Notice Period . Should Company terminate Executives employment without Cause or Executive voluntarily resign Executives employment without
7
Good Reason upon thirty (30) days advance written notice, Company reserves the right to immediately relieve Executive of all job duties, positions and responsibilities and provide Executive with payment of Executives then current Base Salary for thirty (30) days in lieu of any portion of the notice period.
8.7 Resignation of Board or Other Positions . Should Executives employment terminate for any reason, Executive agrees to immediately resign all other positions (including board membership) Executive may hold on behalf of Company, and take all necessary action to accomplish such resignation.
8.8 Application of Section 409A .
(a) Notwithstanding anything set forth in this Agreement to the contrary, no amount payable pursuant to this Agreement which constitutes a deferral of compensation within the meaning of the Treasury Regulations issued pursuant to Section 409A of the Internal Revenue Code of 1986, as amended (the Code), (the Section 409A Regulations) and which is payable upon Executives termination of employment shall be paid unless and until Executive has incurred a separation from service within the meaning of the Section 409A Regulations. Furthermore, to the extent that Executive is a specified employee within the meaning of the Section 409A Regulations as of the date of Executives separation from service, no amount that constitutes a deferral of compensation which is payable on account of Executives separation from service shall be paid to Executive before the date (the Delayed Payment Date) which is the first day of the seventh month after the date of Executives separation from service or, if earlier, the date of Executives death following such separation from service. All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date, with interest at a rate of 5% per annum.
(b) Company intends that income provided to Executive pursuant to this Agreement will not be subject to taxation under Section 409A of the Code and the provisions of this Agreement shall be interpreted and construed in favor of satisfying any applicable requirements of Section 409A of the Code. The payments to Executive pursuant to this Agreement are intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation §1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation §1.409A-1(b)(4). However, Company does not guarantee any particular tax effect for income provided to Executive pursuant to this Agreement. In any event, except for Companys responsibility to withhold applicable income and employment taxes from compensation paid or provided to Executive, Company shall not be responsible for the payment of any applicable taxes on compensation paid or provided to Executive pursuant to this Agreement.
(c) Notwithstanding anything herein to the contrary, the reimbursement of expenses or in-kind benefits provided pursuant to this Agreement shall be subject to the following conditions: (1) the expenses eligible for reimbursement or in-kind benefits in one taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits in any other taxable year; (2) the reimbursement of eligible expenses or in-kind benefits shall be made promptly, subject to Companys applicable policies, but in no event later than the
8
end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.
(d) For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.
9. No Conflict of Interest . During the term of Executives employment with Company, Executive must not engage in any work, paid or unpaid, or other activities that create a conflict of interest. Such work and/or activities shall include, but is not limited to, directly or indirectly competing with Company in any way, or acting as an officer, director, employee, consultant, stockholder, volunteer, lender, or agent of any business enterprise of the same nature as, or which is in direct competition with, the business in which Company is now engaged or in which Company becomes engaged during the term of Executives employment with Company, as may be determined by the Board of Directors in its sole discretion. If Companys Board of Directors believes such a conflict exists during the term of this Agreement, the Board of Directors may ask Executive to choose to discontinue the other work and/or activities or resign employment with Company.
10. Confidentiality and Proprietary Rights . As a condition of employment, Executive agrees to read, sign and abide by Companys Confidentiality and Non-Disclosure Agreement which is attached hereto as Exhibit E .
11. Injunctive Relief . Executive acknowledges that Executives breach of the covenants contained in sections 9-10 (collectively Covenants) would cause irreparable injury to Company and agrees that in the event of any such breach, Company shall be entitled to seek temporary, preliminary and permanent injunctive relief without the necessity of proving actual damages or posting any bond or other security.
12. General Provisions .
12.1 Successors and Assigns . The rights and obligations of Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of Company. Executive shall not be entitled to assign any of Executives rights or obligations under this Agreement.
12.2 Waiver . Either partys failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Agreement.
12.3 Attorneys Fees . Each side will bear its own attorneys fees in any dispute arising under this Agreement unless a statutory section at issue, if any, authorizes the award of attorneys fees to the prevailing party.
12.4 Severability . In the event any provision of this Agreement is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being
9
intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.
12.5 Interpretation; Construction . The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Agreement and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.
12.6 Governing Law . This Agreement will be governed by and construed in accordance with the laws of the United States and the State of California. Each party consents to the jurisdiction and venue of the state or federal courts in San Diego, California, if applicable, in any action, suit, or proceeding arising out of or relating to this Agreement.
12.7 Notices . Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (a) by personal delivery when delivered personally; (b) by overnight courier upon written verification of receipt; (c) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth below, or such other address as either party may specify in writing.
12.8 Survival . Sections 8 (Termination of Executives Employment), 9 (No Conflict of Interest), 10 (Confidentiality and Proprietary Rights), 11 (Injunctive Relief), 12 (General Provisions) and 13 (Entire Agreement) of this Agreement, and any other rights and obligations of either party hereto which by their terms must or may be performed following the termination or expiration of this Agreement, shall survive any such termination or expiration.
13. Entire Agreement . This Agreement, including the Exhibits attached hereto, constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or simultaneous representations, discussions, negotiations, and agreements, whether written or oral. This agreement may be amended or modified only with the written consent of Executive and the Board of Directors. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
10
THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW.
| Dated: | 4/5/11 |
/s/Hany Massarany |
||||
| Hany Massarany |
| GENMARK DIAGNOSTICS, INC. | ||||||
| Dated: | 4/5/11 | By: |
/s/ Chris Gleeson |
|||
| Chris Gleeson | ||||||
| Chairman and Chief Executive Officer | ||||||
11
Exhibit 31.1
CERTIFICATIONS
I, Hany Massarany, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 of Genmark Diagnostics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
Date: May 13, 2011
|
/s/ Hany Massarany |
| Hany Massarany, |
| Chief Executive Officer |
Exhibit 31.2
CERTIFICATIONS
I, Paul Ross, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 of Genmark Diagnostics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
Date: May 13, 2011
|
/s/ Paul Ross |
| Paul Ross, |
| Chief Financial Officer |
Exhibit 32.1
CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Genmark Diagnostic, Inc. (the Company) on Form 10-Q for the quarter ended March 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Periodic Report), we, Hany Massarany, Chief Executive Officer of the Company, and Paul Ross, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. the Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: May 13, 2011 |
/s/ Hany Massarany |
|||||
| Hany Massarany, | ||||||
| Chief Executive Officer | ||||||
| Dated: May 13, 2011 |
/s/ Paul Ross |
|||||
| Paul Ross, | ||||||
| Chief Financial Officer | ||||||